Key Players in India Pulmonary Embolism Market | Top Companies & Insights 2026

Key Players in India Pulmonary Embolism Market

India pulmonary embolism market is a critical and high-growth segment within the country's multi-billion dollar cardiovascular and respiratory care landscape. Major players in this space include Apollo Hospitals, Manipal Hospitals, Fortis Healthcare, Cipla Limited, and Biocon Limited.

India Pulmonary Embolism Market Overview

According to 6Wresearch, the India pulmonary embolism market is undergoing a focused expansion, with the broader pulmonary embolism treatment sector projected to grow, this growth is largely supported by a fundamental change in diagnostic precision, where high-sensitivity D-dimer assays and CT pulmonary angiograms (CTPA) are now standard in top-tier private facilities. Unlike general respiratory ailments, the pulmonary embolism market in India leverages a sophisticated tertiary care infrastructure that serves as a regional hub for emergency thrombectomy and thrombolysis across South Asia.

Competitive Landscape

The competitive landscape of the India pulmonary embolism industry features a dynamic mix of JCI-accredited "Super Hospitals" and leading pharmaceutical manufacturers of anticoagulants. These organizations ensure market diversity by offering comprehensive treatment pathways ranging from standard low-molecular-weight heparin (LMWH) regimens to complex surgical embolectomies.

Below is a list of leading players operating in the India Pulmonary Embolism Market:

1. Apollo Hospitals Enterprise Limited

A healthcare giant providing integrated PE care through dedicated "Centers of Excellence" in cardiology and pulmonology across India.

2. Manipal Health Enterprises

Known for its advanced radiology and interventional pulmonology units that handle complex clot removals and life-saving thromboembolic protocols.

3. Fortis Healthcare Limited

Operates a network of multi-specialty hospitals with a strong focus on emergency VTE management and critical care services.

4. Cipla Limited

A pharmaceutical leader that manufactures essential anticoagulants and thrombolytic agents used in the front-line treatment of blood clots.

5. Biocon Limited

A major enoxaparin manufacturer in India, providing a wide selection of biosimilar anticoagulants in pre-filled syringes for hospital use.

6. Gleneagles Hospitals

Recognized for its interventional pulmonology and sleep medicine departments, specializing in the diagnosis of inflammatory mimics of PE.

7. Venus Remedies Limited

A prominent manufacturer of critical care injectables, specializing in the production and export of high-quality enoxaparin injections.

8. Medanta - The Medicity

Combines top-tier vascular surgery and interventional radiology to offer minimally invasive clot fragmentation and aspiration therapies.

9. Bharat Serums and Vaccines Limited (BSV)

Manufacturer of the leading "Lonopin" brand of Enoxaparin Sodium, widely used in India for the prevention and treatment of DVT and PE.

10. Emcure Pharmaceuticals Limited

A significant pharmaceutical player with a strong presence in the anticoagulant segment, offering various dosages of blood-thinning medications.

11. Gland Pharma Limited

A global injectable-focused pharmaceutical company that produces high-purity enoxaparin sodium injections for the domestic market.

12. Apollo Diagnostics

Provides widespread access to critical D-dimer testing and advanced serological assays required for early PE diagnosis.

13. Celon Laboratories Private Limited

Focuses on critical care and oncology, manufacturing cost-effective enoxaparin injections used in prolonged hospitalization protocols.

Key Players in India Pulmonary Embolism Market: FAQs